secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-09-23T23:59:59+00:00
Accession:  0000950170-22-018819
Event type: debt
Sentiment:  positive
Materiality: 0.60
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax prepays $21.5M loan, terminates Hercules Capital credit agreement
------------------------------------------------------------------------

- Prepaid $21.5M to Hercules Capital to satisfy all principal, interest, and fees under Feb 2020 loan; includes $1.0M end-of-term fee and $0.4M prepayment fee.
- Hercules released all security interests on Syndax assets; loan agreement fully terminated as of September 23, 2022.
- Prepayment does not alter prior guidance: current cash sufficient to fund operations into second half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000095017022018819/0000950170-22-018819-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000095017022018819/sndx-20220919.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-018819

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer